Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.25 - $2.51 $9,712 - $19,502
7,770 Added 4.24%
190,975 $259,000
Q3 2023

Nov 14, 2023

SELL
$2.15 - $3.59 $2,453 - $4,096
-1,141 Reduced 0.62%
183,205 $428,000
Q4 2022

Feb 10, 2023

BUY
$2.81 - $39.7 $221 - $3,136
79 Added 0.04%
184,346 $593,000
Q3 2022

Nov 14, 2022

BUY
$3.97 - $42.7 $42,082 - $452,620
10,600 Added 6.1%
184,267 $682,000
Q2 2022

Aug 12, 2022

BUY
$5.93 - $15.61 $342,765 - $902,289
57,802 Added 49.89%
173,667 $1.03 Million
Q1 2022

May 13, 2022

BUY
$5.06 - $13.8 $87,178 - $237,760
17,229 Added 17.47%
115,865 $1.6 Million
Q4 2021

Feb 14, 2022

SELL
$2.92 - $42.3 $99,230 - $1.44 Million
-33,983 Reduced 25.62%
98,636 $1.19 Million
Q3 2021

Nov 12, 2021

BUY
$3.4 - $8.3 $4,620 - $11,279
1,359 Added 1.04%
132,619 $468,000
Q2 2021

Aug 13, 2021

BUY
$5.2 - $8.13 $682,552 - $1.07 Million
131,260 New
131,260 $1.07 Million

Others Institutions Holding LGVN

About Longeveron Inc.


  • Ticker LGVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,925,940
  • Market Cap $12.2M
  • Description
  • Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...
More about LGVN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.